Best Practices Forum: The role of icosapent ethyl for CV risk reduction
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
Perspectives from family practice, diabetology, and cardiology
Overview & Objectives
Perspectives from primary care, diabetology and cardiology.
Learning Objectives:
- To review the role of serum triglycerides as a risk marker vs. a risk factor
- To differentiate icosapent ethyl from standard fish oils
- To best apply the findings from the REDUCE-IT study to clinical practice
Accreditation
This program is NOT accredited.
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.
Faculty
Faculty
Agenda
Agenda
| Program Chapter | Duration (Min:Sec) |
|---|---|
| Are serum triglycerides a risk factor? | |
| Do fish oils reduce CV risk? | |
| How does icosapent ethyl differ from fish oils? | |
| What are the main results of the REDUCE-IT study? | |
| What is the mechanism of benefit? | |
| How should we use icosapent ethyl in our practices? |
Sponsorship
This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.
Links & Resources
Program slides:
This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization. A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.
Access CCRN Member Resource Library.